[S02DA03, antipyrine, The risk or severity of hypertension can be increased when Sufentanil is combined with Antipyrine.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Sufentanil.]
[L04AA27, fingolimod, Sufentanil may increase the bradycardic activities of Fingolimod.]
[M03AB01, succinylcholine, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Sufentanil.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Sulindac is combined with Sufentanil.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Sulpiride is combined with Sufentanil.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Sufentanil is combined with Sulthiame.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Sufentanil is combined with Azapropazone.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Temazepam.]
[R03CC03, terbutaline, The risk or severity of hypertension can be increased when Sufentanil is combined with Terbutaline.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Sufentanil is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Apomorphine.]
[L04AX02, thalidomide, Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, The therapeutic efficacy of Theobromine can be decreased when used in combination with Sufentanil.]
[R06AD03, thiethylperazine, The risk or severity of hypotension and CNS depression can be increased when Thiethylperazine is combined with Sufentanil.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Thiopental is combined with Sufentanil.]
[N05AB08, thioproperazine, The risk or severity of hypotension and CNS depression can be increased when Thioproperazine is combined with Sufentanil.]
[N05AC02, thioridazine, The risk or severity of hypotension and CNS depression can be increased when Thioridazine is combined with Sufentanil.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Sufentanil is combined with Thiothixene.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Sufentanil is combined with Moxisylyte.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Sufentanil is combined with Tiapride.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Tilidine.]
[S01ED01, timolol, Sufentanil may decrease the antihypertensive activities of Timolol.]
[M02AX02, tolazoline, Sufentanil may decrease the antihypertensive activities of Tolazoline.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Tolmetin is combined with Sufentanil.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Sufentanil is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Sufentanil is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Sufentanil.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Sufentanil is combined with Tretinoin.]
[C03DB02, triamterene, The therapeutic efficacy of Triamterene can be decreased when used in combination with Sufentanil.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Triazolam.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Sufentanil.]
[A03AB12, mepenzolate, The risk or severity of adverse effects can be increased when Mepenzolate is combined with Sufentanil.]
[N05AB06, trifluoperazine, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Sufentanil.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Sufentanil is combined with Trifluperidol.]
[N05AA05, triflupromazine, The risk or severity of adverse effects can be increased when Triflupromazine is combined with Sufentanil.]
[N04AA01, trihexyphenidyl, The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Sufentanil.]
[A03AA05, trimebutine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Sufentanil.]
[R06AD01, trimeprazine, The risk or severity of hypotension and CNS depression can be increased when Alimemazine is combined with Sufentanil.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Sufentanil.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Trimethaphan is combined with Sufentanil.]
[N06AA06, trimipramine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Trimipramine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Sufentanil.]
[A03BB01, butylscopolamine, The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Sufentanil.]
[J01FA08, troleandomycin, The metabolism of Sufentanil can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Sufentanil is combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Sufentanil.]
[C09CA09, azilsartan medoxomil, Sufentanil may decrease the antihypertensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Tubocurarine is combined with Sufentanil.]
[A10BH05, linagliptin, The metabolism of Sufentanil can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Sufentanil can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Sufentanil can be decreased when combined with Telaprevir.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Ezogabine.]
[R03AC18, indacaterol, The risk or severity of hypertension can be increased when Sufentanil is combined with Indacaterol.]
[B01AC24, ticagrelor, Sufentanil can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C08DA01, verapamil, The metabolism of Sufentanil can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Sufentanil can be decreased when combined with Viloxazine.]
[C04AX07, vincamine, Sufentanil may decrease the antihypertensive activities of Vincamine.]
[S01AA13, fusidic acid, The metabolism of Sufentanil can be decreased when combined with Fusidic acid.]
[N01AX15, xenon, The therapeutic efficacy of Xenon can be increased when used in combination with Sufentanil.]
[C03BA10, xipamide, The therapeutic efficacy of Xipamide can be decreased when used in combination with Sufentanil.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Sufentanil is combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Sufentanil can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Levetiracetam.]
[L01ED01, crizotinib, Crizotinib may increase the bradycardic activities of Sufentanil.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Sufentanil is combined with Ziprasidone.]
[G03AC10, drospirenone, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Sufentanil.]
[N02BA01, aspirin, The risk or severity of hypertension can be increased when Sufentanil is combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, Ruxolitinib may increase the bradycardic activities of Sufentanil.]
[G04BD07, tolterodine, The risk or severity of adverse effects can be increased when Tolterodine is combined with Sufentanil.]
[C07AB03, atenolol, Sufentanil may decrease the antihypertensive activities of Atenolol.]
[J02AC03, voriconazole, The metabolism of Sufentanil can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Atracurium is combined with Sufentanil.]
[S01FA01, atropine, The risk or severity of adverse effects can be increased when Atropine is combined with Sufentanil.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Sufentanil.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Sufentanil is combined with Lorcaserin.]
[G04BD12, mirabegron, The risk or severity of hypertension can be increased when Sufentanil is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Sufentanil can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Sufentanil can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Sufentanil can be decreased when it is combined with Enzalutamide.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Sufentanil.]
[C01CA18, octopamine, The risk or severity of hypertension can be increased when Sufentanil is combined with Octopamine.]
[L01EX05, regorafenib, Sufentanil may increase the bradycardic activities of Regorafenib.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Barbital is combined with Sufentanil.]
[J05AE04, nelfinavir, The metabolism of Sufentanil can be decreased when combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Sufentanil is combined with Rasagiline.]
[C08CA13, lercanidipine, Sufentanil may decrease the antihypertensive activities of Lercanidipine.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Sufentanil is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.]
[L04AA29, tofacitinib, Sufentanil may increase the bradycardic activities of Tofacitinib.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Sufentanil.]
[R06AC06, thonzylamine, The risk or severity of adverse effects can be increased when Thonzylamine is combined with Sufentanil.]
[G04BD10, darifenacin, The risk or severity of adverse effects can be increased when Darifenacin is combined with Sufentanil.]
[N01AB02, chloroform, The therapeutic efficacy of Chloroform can be increased when used in combination with Sufentanil.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Sufentanil is combined with Diethyl ether.]
[H01CB05, pasireotide, Sufentanil may increase the bradycardic activities of Pasireotide.]
[G04BE03, sildenafil, The risk or severity of hypotension can be increased when Sildenafil is combined with Sufentanil.]
[C04AX11, bencyclane, Sufentanil may increase the bradycardic activities of Bencyclane.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Sufentanil.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Sufentanil is combined with Pomalidomide.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Sufentanil is combined with Benorilate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Sufentanil is combined with Benperidol.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Sufentanil.]
[A06AX06, tegaserod, The risk or severity of serotonin syndrome can be increased when Sufentanil is combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Benzocaine.]
[M01AH01, celecoxib, The risk or severity of hypertension can be increased when Celecoxib is combined with Sufentanil.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Sufentanil is combined with Naratriptan.]
[N04AC01, benztropine, The risk or severity of adverse effects can be increased when Benzatropine is combined with Sufentanil.]
[L01EC02, dabrafenib, The serum concentration of Sufentanil can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Sufentanil is combined with Benzydamine.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Sufentanil is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The risk or severity of serotonin syndrome can be increased when Sufentanil is combined with Levomilnacipran.]
[C08EA02, bepridil, Sufentanil may decrease the antihypertensive activities of Bepridil.]
[C02KX05, riociguat, Sufentanil may decrease the antihypertensive activities of Riociguat.]
[C02KX04, macitentan, Sufentanil may decrease the antihypertensive activities of Macitentan.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Vortioxetine.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Sufentanil can be decreased when combined with Simeprevir.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Sufentanil is combined with Vigabatrin.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Sufentanil.]
[C01CA27, droxidopa, The risk or severity of hypertension can be increased when Sufentanil is combined with Droxidopa.]
[C07AB04, acebutolol, Sufentanil may decrease the antihypertensive activities of Acebutolol.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Sufentanil is combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Sufentanil can be increased when combined with Metreleptin.]
[S01ED02, betaxolol, Sufentanil may decrease the antihypertensive activities of Betaxolol.]
[C02CC01, bethanidine, Sufentanil may decrease the antihypertensive activities of Bethanidine.]
[L01ED02, ceritinib, Sufentanil may increase the bradycardic activities of Ceritinib.]
[A03BA03, hyoscyamine, The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Sufentanil.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Sufentanil is combined with Alfaxalone.]
[A10BK03, empagliflozin, The risk or severity of adverse effects can be increased when Sufentanil is combined with Empagliflozin.]
[R03AC19, olodaterol, The risk or severity of hypertension can be increased when Sufentanil is combined with Olodaterol.]
[D11AA01, glycopyrronium, The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Sufentanil.]
[N05CM19, suvorexant, Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[N05AA04, acepromazine, The risk or severity of hypotension and CNS depression can be increased when Acepromazine is combined with Sufentanil.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Sufentanil.]
[A06AH03, naloxegol, The risk or severity of adverse effects can be increased when Sufentanil is combined with Naloxegol.]
[N04AA02, biperiden, The risk or severity of adverse effects can be increased when Biperiden is combined with Sufentanil.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Sufentanil.]
[N06AX11, mirtazapine, Sufentanil may increase the serotonergic activities of Mirtazapine.]
[A03AA09, difemerine, The risk or severity of adverse effects can be increased when Difemerine is combined with Sufentanil.]
[C01EB17, ivabradine, Sufentanil may increase the bradycardic activities of Ivabradine.]
[A07DA06, eluxadoline, The risk or severity of constipation can be increased when Sufentanil is combined with Eluxadoline.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Sufentanil is combined with Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Sufentanil is combined with Flibanserin.]
[A06AD03, magnesium peroxide, The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Sufentanil.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Cariprazine.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Sufentanil is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Sufentanil is combined with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Sufentanil is combined with Acetazolamide.]
[N05AB07, acetophenazine, The risk or severity of hypotension and CNS depression can be increased when Acetophenazine is combined with Sufentanil.]
[J02AC05, isavuconazole, The metabolism of Sufentanil can be decreased when combined with Isavuconazole.]
[B01AC27, selexipag, Sufentanil may decrease the antihypertensive activities of Selexipag.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Aprobarbital is combined with Sufentanil.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Sufentanil is combined with Alminoprofen.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Brivaracetam.]
[L01XX52, venetoclax, The metabolism of Sufentanil can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Bromazepam.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Bromocriptine.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sufentanil.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Sufentanil is combined with Amineptine.]
[C08CA01, amlodipine, Sufentanil may decrease the antihypertensive activities of Amlodipine.]
[N01AH05, anileridine, The therapeutic efficacy of Anileridine can be increased when used in combination with Sufentanil.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Aniracetam.]
[C03CA02, bumetanide, The therapeutic efficacy of Bumetanide can be decreased when used in combination with Sufentanil.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Sufentanil.]
[C07AA19, bupranolol, Sufentanil may decrease the antihypertensive activities of Bupranolol.]
[N07BC01, buprenorphine, Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Sufentanil.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Sufentanil is combined with Arsenic trioxide.]
[N06DA03, rivastigmine, Sufentanil may increase the bradycardic activities of Rivastigmine.]
[N02AF01, butorphanol, The therapeutic efficacy of Sufentanil can be decreased when used in combination with Butorphanol.]
[S01GX07, azelastine, Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Sufentanil.]
[L01EF02, ribociclib, The metabolism of Sufentanil can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Sufentanil is combined with Balsalazide.]
[R03CC12, bambuterol, The risk or severity of hypertension can be increased when Sufentanil is combined with Bambuterol.]
[A06AH05, naldemedine, The therapeutic efficacy of Sufentanil can be decreased when used in combination with Naldemedine.]
[N02BF02, pregabalin, The therapeutic efficacy of Sufentanil can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Sufentanil is combined with Beclamide.]
[C09AA07, benazepril, Sufentanil may decrease the antihypertensive activities of Benazepril.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Sufentanil is combined with Oxybuprocaine.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Sufentanil.]
[J05AE09, tipranavir, The metabolism of Sufentanil can be decreased when combined with Tipranavir.]
[L01EX10, midostaurin, The metabolism of Sufentanil can be decreased when combined with Midostaurin.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Sufentanil is combined with Safinamide.]
[C07AB07, bisoprolol, Sufentanil may decrease the antihypertensive activities of Bisoprolol.]
[R03AC17, bitolterol, The risk or severity of hypertension can be increased when Sufentanil is combined with Bitolterol.]
[J05AG03, efavirenz, The metabolism of Sufentanil can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, Sufentanil may increase the bradycardic activities of Bopindolol.]
[N04AA11, bornaprine, The risk or severity of adverse effects can be increased when Bornaprine is combined with Sufentanil.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Sufentanil is combined with Nesiritide.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Sufentanil is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Brotizolam.]
[C03DA03, canrenone, The therapeutic efficacy of Canrenone can be decreased when used in combination with Sufentanil.]
[C04AX20, buflomedil, The risk or severity of hypertension can be increased when Sufentanil is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Sufentanil is combined with Bumadizone.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Butobarbital is combined with Sufentanil.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Sufentanil is combined with Butriptyline.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Sufentanil.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Sufentanil is combined with Vinylbital.]
[C09AA01, captopril, Sufentanil may decrease the antihypertensive activities of Captopril.]
[L02BB05, apalutamide, The metabolism of Sufentanil can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Sufentanil can be increased when combined with Carbamazepine.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Sufentanil.]
[A03AA03, camylofine, The risk or severity of adverse effects can be increased when Camylofin is combined with Sufentanil.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Carbinoxamine.]
[C07AG02, carvedilol, Sufentanil may decrease the antihypertensive activities of Carvedilol.]
[B02BX09, fostamatinib, The risk or severity of hypotension can be increased when Fostamatinib is combined with Sufentanil.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Sufentanil.]
[C07AB08, celiprolol, Sufentanil may decrease the antihypertensive activities of Celiprolol.]
[L01XX62, ivosidenib, The metabolism of Sufentanil can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Sufentanil can be decreased when combined with Stiripentol.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Sufentanil.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Sufentanil is combined with Carbromal.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Sufentanil.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Sufentanil is combined with Lornoxicam.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Sufentanil.]
[R03BB08, revefenacin, The risk or severity of adverse effects can be increased when Revefenacin is combined with Sufentanil.]
[A06AX05, prucalopride, The therapeutic efficacy of Prucalopride can be decreased when used in combination with Sufentanil.]
[C09AA08, cilazapril, Sufentanil may decrease the antihypertensive activities of Cilazapril.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Sufentanil is combined with Cinitapride.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Sufentanil.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Sufentanil is combined with Siponimod.]
[J01FA09, clarithromycin, The metabolism of Sufentanil can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Sufentanil.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Sufentanil is combined with Brexanolone.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Clobazam.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Sufentanil.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Cloxazolam.]
[C09CA06, candesartan, Sufentanil may decrease the antihypertensive activities of Candesartan.]
[N05AA06, cyamemazine, The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Sufentanil.]
[C03BX03, cicletanine, The therapeutic efficacy of Cicletanine can be decreased when used in combination with Sufentanil.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Sufentanil.]
[N07XX11, pitolisant, The serum concentration of Sufentanil can be decreased when it is combined with Pitolisant.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Cyclothiazide can be decreased when used in combination with Sufentanil.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Yohimbine.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Sufentanil.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Sufentanil.]
[N03AX25, cenobamate, The serum concentration of Sufentanil can be decreased when it is combined with Cenobamate.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sufentanil.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Dezocine.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Sufentanil is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Sufentanil is combined with Lumateperone.]
[J05AE05, amprenavir, The metabolism of Sufentanil can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Sufentanil is combined with Frovatriptan.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Sufentanil is combined with Dutasteride.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Sufentanil is combined with Dichloralphenazone.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Sufentanil is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Sufentanil.]
[M01AH02, rofecoxib, The risk or severity of hypertension can be increased when Rofecoxib is combined with Sufentanil.]
[C08CA16, clevidipine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Clevidipine.]
[C01BD07, dronedarone, The metabolism of Sufentanil can be decreased when combined with Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Sufentanil is combined with Valpromide.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Sufentanil is combined with Chlordiazepoxide.]
[C02AA06, methoserpidine, Sufentanil may decrease the antihypertensive activities of Methoserpidine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Sufentanil.]
[A03AA08, dihexyverine, The risk or severity of adverse effects can be increased when Dihexyverine is combined with Sufentanil.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Sufentanil is combined with Opicapone.]
[C01CA14, dopexamine, The risk or severity of hypertension can be increased when Sufentanil is combined with Dopexamine.]
[G04BD09, trospium, The risk or severity of adverse effects can be increased when Trospium is combined with Sufentanil.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Sufentanil is combined with Droxicam.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Sufentanil is combined with Selpercatinib.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Sufentanil is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Sufentanil is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Sufentanil is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Sufentanil.]
[C08CA17, levamlodipine, Sufentanil may decrease the antihypertensive activities of Levamlodipine.]
[N05CD14, remimazolam, The risk or severity of sedation can be increased when Sufentanil is combined with Remimazolam.]
[L04AC19, satralizumab, The serum concentration of Sufentanil can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Sufentanil is combined with Oliceridine.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Sufentanil.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sufentanil.]
[N05AF03, chlorprothixene, The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Sufentanil.]
[C03BA04, chlorthalidone, The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Sufentanil.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Sufentanil.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Etifoxine.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Sufentanil is combined with Ethenzamide.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethyl loflazepate.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Sufentanil is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Sufentanil is combined with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Sufentanil can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Sufentanil can be decreased when combined with Lonafarnib.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Sufentanil is combined with Naxitamab.]
[P03AX07, abametapir, The serum concentration of Sufentanil can be increased when it is combined with Abametapir.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Sufentanil is combined with Vericiguat.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Sufentanil is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Sufentanil is combined with Felbamate.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Sufentanil is combined with Fenbufen.]
[C01CA19, fenoldopam, Sufentanil may decrease the antihypertensive activities of Fenoldopam.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Sufentanil is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Sufentanil is combined with Finasteride.]
[R03CC15, formoterol, The risk or severity of hypertension can be increased when Sufentanil is combined with Formoterol.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Sufentanil.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Sufentanil is combined with Trichloroethylene.]
[H04AA02, dasiglucagon, Sufentanil may decrease the antihypertensive activities of Dasiglucagon.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Sufentanil is combined with Gabapentin.]
[N07CA02, cinnarizine, Cinnarizine may increase the bradycardic activities of Sufentanil.]
[L01XX73, sotorasib, The serum concentration of Sufentanil can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Sufentanil can be decreased when combined with Ciprofloxacin.]
[N06AB04, citalopram, The risk or severity of serotonin syndrome can be increased when Sufentanil is combined with Citalopram.]
[C03DA05, finerenone, The therapeutic efficacy of Finerenone can be decreased when used in combination with Sufentanil.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Sufentanil is combined with Fexinidazole.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Sufentanil.]
[R03CC13, clenbuterol, The risk or severity of hypertension can be increased when Sufentanil is combined with Clenbuterol.]
[N06AX25, St. John's wort extract, The metabolism of Sufentanil can be increased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Sufentanil.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Levobupivacaine.]
[N06AA04, clomipramine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Clomipramine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Sufentanil.]
[C01EB24, mavacamten, The serum concentration of Sufentanil can be decreased when it is combined with Mavacamten.]
[C03BA03, clopamide, The therapeutic efficacy of Clopamide can be decreased when used in combination with Sufentanil.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Sufentanil is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Sufentanil is combined with Granisetron.]
[N05AH02, clozapine, The risk or severity of adverse effects can be increased when Clozapine is combined with Sufentanil.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Halazepam.]
[H01AC08, somatrogon, The metabolism of Sufentanil can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of adverse effects can be increased when Cocaine is combined with Sufentanil.]
[C02KB01, metyrosine, Sufentanil may increase the sedative activities of Metyrosine.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Sufentanil is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Sufentanil.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Sufentanil.]
[A03AB10, hexocyclium, The risk or severity of adverse effects can be increased when Hexocyclium is combined with Sufentanil.]
[A03BB06, homatropine methylbromide, The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Sufentanil.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Sufentanil is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Sufentanil is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Ifenprodil.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Sufentanil is combined with Imidazole salicylate.]
[J01FA15, telithromycin, The metabolism of Sufentanil can be decreased when combined with Telithromycin.]
[B01AC10, indobufen, The risk or severity of hypertension can be increased when Sufentanil is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Desloratadine is combined with Sufentanil.]
[M01AH03, valdecoxib, The risk or severity of hypertension can be increased when Valdecoxib is combined with Sufentanil.]
[H01AX01, pegvisomant, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Sufentanil.]
[A03AX10, isometheptene, The risk or severity of hypertension can be increased when Sufentanil is combined with Isometheptene.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Sufentanil is combined with Almotriptan.]
[M01AH04, parecoxib, The risk or severity of hypertension can be increased when Sufentanil is combined with Parecoxib.]
[J02AC02, itraconazole, The metabolism of Sufentanil can be decreased when combined with Itraconazole.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Ketazolam.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Sufentanil is combined with Kebuzone.]
[J02AC04, posaconazole, The metabolism of Sufentanil can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, Sufentanil may increase the hypotensive activities of Lacidipine.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Sufentanil.]
[N03AX09, lamotrigine, The risk or severity of adverse effects can be increased when Lamotrigine is combined with Sufentanil.]
[N07BC04, lofexidine, The therapeutic efficacy of Sufentanil can be increased when used in combination with Lofexidine.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Sufentanil is combined with Lonazolac.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Lormetazepam.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Sufentanil is combined with Loxoprofen.]
[C09AA03, lisinopril, Sufentanil may decrease the antihypertensive activities of Lisinopril.]
[A06AD01, magnesium carbonate, The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Sufentanil.]
[C08CA11, manidipine, Sufentanil may decrease the antihypertensive activities of Manidipine.]
[A03AA04, mebeverine, The risk or severity of adverse effects can be increased when Mebeverine is combined with Sufentanil.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Medifoxamine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Sufentanil is combined with Mefenorex.]
[C07AA14, mepindolol, Sufentanil may increase the bradycardic activities of Mepindolol.]
[N04AA03, methixene, The risk or severity of adverse effects can be increased when Metixene is combined with Sufentanil.]
[C04AX01, cyclandelate, Sufentanil may increase the bradycardic activities of Cyclandelate.]
[R03CB02, methoxyphenamine, Methoxyphenamine may increase the analgesic activities of Sufentanil.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclobarbital.]
[C03DA04, eplerenone, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Sufentanil.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Sufentanil is combined with Melperone.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Sufentanil.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Minaprine.]
[S01XA18, cyclosporine, The metabolism of Sufentanil can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Sufentanil is combined with Moclobemide.]
[R06AX02, cyproheptadine, The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Sufentanil.]
[C09AA13, moexipril, Sufentanil may decrease the antihypertensive activities of Moexipril.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Sufentanil is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Sufentanil is combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Sufentanil can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, Sufentanil may decrease the antihypertensive activities of Moxonidine.]
[G04BE09, vardenafil, The risk or severity of hypotension can be increased when Vardenafil is combined with Sufentanil.]
[M01AH05, etoricoxib, The risk or severity of hypertension can be increased when Sufentanil is combined with Etoricoxib.]
[G03XA01, danazol, The metabolism of Sufentanil can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Sufentanil is combined with Dantrolene.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Sufentanil is combined with Deanol.]
[C02CC04, debrisoquin, Sufentanil may decrease the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.]
[M01AX01, nabumetone, The risk or severity of hypertension can be increased when Nabumetone is combined with Sufentanil.]
[N07BB05, nalmefene, The therapeutic efficacy of Sufentanil can be decreased when used in combination with Nalmefene.]
[B05XA15, potassium lactate, The therapeutic efficacy of Potassium lactate can be decreased when used in combination with Sufentanil.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Nordazepam.]
[C07AB12, nebivolol, Sufentanil may decrease the antihypertensive activities of Nebivolol.]
[N06AX06, nefazodone, The metabolism of Sufentanil can be decreased when combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Niaprazine.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Sufentanil.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Tiagabine.]
[C01CA23, theodrenaline, The risk or severity of hypertension can be increased when Sufentanil is combined with Theodrenaline.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Sufentanil.]
[C01CA05, norfenefrine, The risk or severity of hypertension can be increased when Sufentanil is combined with Norfenefrine.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Sufentanil is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Sufentanil is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of adverse effects can be increased when Solifenacin is combined with Sufentanil.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Sufentanil is combined with Olsalazine.]
[N06AA01, desipramine, The risk or severity of adverse effects can be increased when Desipramine is combined with Sufentanil.]
[H01BA02, desmopressin, The risk or severity of hyponatremia can be increased when Sufentanil is combined with Desmopressin.]
[C09XA02, aliskiren, Sufentanil may decrease the antihypertensive activities of Aliskiren.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Sufentanil is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Sufentanil can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Oxiracetam.]
[N04AA08, dexetimide, The risk or severity of adverse effects can be increased when Dexetimide is combined with Sufentanil.]
[G04BD04, oxybutynin, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Sufentanil.]
[A08AA04, dexfenfluramine, The risk or severity of serotonin syndrome can be increased when Sufentanil is combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Sufentanil.]
[N06BA02, dextroamphetamine, Amphetamine may increase the analgesic activities of Sufentanil.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Sufentanil.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Sufentanil.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Sufentanil is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of serotonin syndrome can be increased when Sufentanil is combined with Paroxetine.]
[B01AC04, clopidogrel, Sufentanil can cause a decrease in the absorption of Clopidogrel resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Sufentanil is combined with Diamorphine.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Diazepam.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Sufentanil is combined with Phenacemide.]
[V03AH01, diazoxide, Sufentanil may decrease the antihypertensive activities of Diazoxide.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Sufentanil is combined with Phensuximide.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Sufentanil is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Sufentanil.]
[S01EC02, dichlorphenamide, The therapeutic efficacy of Diclofenamide can be decreased when used in combination with Sufentanil.]
[S01BC03, diclofenac, The risk or severity of hypertension can be increased when Diclofenac is combined with Sufentanil.]
[A03AA07, dicyclomine, The risk or severity of adverse effects can be increased when Dicyclomine is combined with Sufentanil.]
[C02DG01, pinacidil, Sufentanil may decrease the antihypertensive activities of Pinacidil.]
[A03AX04, pinaverium, Sufentanil may increase the bradycardic activities of Pinaverium.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Sufentanil is combined with Pipamperone.]
[A03AB14, pipenzolate, The risk or severity of adverse effects can be increased when Pipenzolate is combined with Sufentanil.]
[R03CC07, pirbuterol, The risk or severity of hypertension can be increased when Sufentanil is combined with Pirbuterol.]
[C03CA03, piretanide, The therapeutic efficacy of Piretanide can be decreased when used in combination with Sufentanil.]
[A08AA03, diethylpropion, Diethylpropion may increase the analgesic activities of Sufentanil.]
[C08CA03, isradipine, The metabolism of Sufentanil can be decreased when combined with Isradipine.]
[A03AB11, poldine, The risk or severity of adverse effects can be increased when Poldine is combined with Sufentanil.]
[N02BA11, diflunisal, The risk or severity of hypertension can be increased when Sufentanil is combined with Diflunisal.]
[C01AA05, digoxin, Digoxin may increase the bradycardic activities of Sufentanil.]
[C02DB01, dihydralazine, Sufentanil may decrease the antihypertensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, The risk or severity of hypertension can be increased when Sufentanil is combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Sufentanil.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Sufentanil.]
[J05AE08, atazanavir, The metabolism of Sufentanil can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, Sufentanil may decrease the antihypertensive activities of Treprostinil.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Sufentanil can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Sufentanil is combined with Dimenhydrinate.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Sufentanil is combined with Pridinol.]
[R06AB03, dimethindene, The risk or severity of adverse effects can be increased when Dimetindene is combined with Sufentanil.]
[R03CC08, procaterol, The risk or severity of hypertension can be increased when Sufentanil is combined with Procaterol.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Sufentanil is combined with Progabide.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Sufentanil is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Sufentanil is combined with Proglumetacin.]
[R06AA02, diphenhydramine, The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Sufentanil.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Sufentanil is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Quazepam.]
[C09AA06, quinapril, Sufentanil may decrease the antihypertensive activities of Quinapril.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Sufentanil is combined with Dipyridamole.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Sufentanil is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of adverse effects can be increased when Cisapride is combined with Sufentanil.]
[C09AA05, ramipril, Sufentanil may decrease the antihypertensive activities of Ramipril.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Sufentanil.]
[R03CC14, reproterol, The risk or severity of hypertension can be increased when Sufentanil is combined with Reproterol.]
[C01BA03, disopyramide, The risk or severity of adverse effects can be increased when Disopyramide is combined with Sufentanil.]
[S02AA12, rifamycin SV, The metabolism of Sufentanil can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Sufentanil can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Sufentanil is combined with Riluzole.]
[N05AX08, risperidone, Sufentanil may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Sufentanil.]
[A04AD12, aprepitant, The metabolism of Sufentanil can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Sufentanil.]
[G04BE08, tadalafil, Sufentanil may decrease the antihypertensive activities of Tadalafil.]
[S01BC05, ketorolac, The risk or severity of hypertension can be increased when Ketorolac is combined with Sufentanil.]
[C02KX02, ambrisentan, Sufentanil may decrease the antihypertensive activities of Ambrisentan.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Sufentanil is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of hypertension can be increased when Sufentanil is combined with Salmeterol.]
[C01CA07, dobutamine, The risk or severity of hypertension can be increased when Sufentanil is combined with Dobutamine.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Sufentanil is combined with Dopamine.]
[N06AA16, dothiepin, The risk or severity of adverse effects can be increased when Dosulepin is combined with Sufentanil.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Doxapram is combined with Sufentanil.]
[N06AA12, doxepin, The risk or severity of adverse effects can be increased when Doxepin is combined with Sufentanil.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Sufentanil.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.]
[N06AB06, sertraline, The risk or severity of serotonin syndrome can be increased when Sufentanil is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Sufentanil is combined with Sevoflurane.]
[N05AD08, droperidol, The risk or severity of hypertension can be increased when Sufentanil is combined with Droperidol.]
[A08AA10, sibutramine, The risk or severity of serotonin syndrome can be increased when Sufentanil is combined with Sibutramine.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Sufentanil.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Sufentanil.]
[C09AA11, spirapril, Sufentanil may decrease the antihypertensive activities of Spirapril.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Sufentanil is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Sufentanil.]
[C07AB13, talinolol, Sufentanil may decrease the antihypertensive activities of Talinolol.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Tenoxicam is combined with Sufentanil.]
[G04CA03, terazosin, Sufentanil may decrease the antihypertensive activities of Terazosin.]
[G04BD05, terodiline, Sufentanil may increase the bradycardic activities of Terodiline.]
[C07AA16, tertatolol, Sufentanil may increase the bradycardic activities of Tertatolol.]
[S01GA02, tetrahydrozoline, The risk or severity of hypertension can be increased when Sufentanil is combined with Tetryzoline.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Sufentanil is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Sufentanil is combined with Thiopropazate.]
[G04BD01, emepronium, The risk or severity of adverse effects can be increased when Emepronium is combined with Sufentanil.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Tianeptine.]
[C09AA02, enalapril, Sufentanil may decrease the antihypertensive activities of Enalapril.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Tofisopam.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Sufentanil is combined with Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Sufentanil is combined with Toloxatone.]
[N06BA09, atomoxetine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Sufentanil.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Sufentanil.]
[C03CA04, torsemide, The therapeutic efficacy of Torasemide can be decreased when used in combination with Sufentanil.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Sufentanil is combined with Tramazoline.]
[C09AA10, trandolapril, Sufentanil may decrease the antihypertensive activities of Trandolapril.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Sufentanil is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Sufentanil is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Sufentanil is combined with Triclofos.]
[A03AB08, tridihexethyl, The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Sufentanil.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Sufentanil.]
[N04AA12, tropatepine, The risk or severity of adverse effects can be increased when Tropatepine is combined with Sufentanil.]
[R03CC11, tulobuterol, The risk or severity of hypertension can be increased when Sufentanil is combined with Tulobuterol.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Sufentanil.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Urapidil.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Sufentanil is combined with Veralipride.]
[S01FB02, ephedrine, The risk or severity of hypertension can be increased when Sufentanil is combined with Ephedrine.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Epinastine.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Sufentanil is combined with Venlafaxine.]
[C01CX07, xamoterol, The risk or severity of hypertension can be increased when Sufentanil is combined with Xamoterol.]
[S01GA03, xylometazoline, The risk or severity of hypertension can be increased when Sufentanil is combined with Xylometazoline.]
[C08CA12, mepirodipine, The metabolism of Sufentanil can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The risk or severity of hypertension can be increased when Epinephrine is combined with Sufentanil.]
[C09AA15, zofenopril, Sufentanil may decrease the antihypertensive activities of Zofenopril.]
[N05CF02, zolpidem, Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Sufentanil is combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Sufentanil is combined with Zonisamide.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Sufentanil is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Zotepine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Guanfacine.]
[B01AC11, iloprost, The risk or severity of adverse effects can be increased when Sufentanil is combined with Iloprost.]
[C01BG01, moricizine, The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Sufentanil.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Sufentanil is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The metabolism of Sufentanil can be decreased when combined with Ergotamine.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Sufentanil.]
[S01AA17, erythromycin, The metabolism of Sufentanil can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Estazolam.]
[C01CA15, gepefrine, Gepefrine may increase the analgesic activities of Sufentanil.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sufentanil.]
[V03AF05, amifostine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Amifostine.]
[N04AA05, profenamine, The risk or severity of adverse effects can be increased when Profenamine is combined with Sufentanil.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Sufentanil.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethotoin.]
[M01AC06, meloxicam, The risk or severity of hypertension can be increased when Sufentanil is combined with Meloxicam.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethylmorphine.]
[C01CA01, etilefrine, The risk or severity of hypertension can be increased when Sufentanil is combined with Etilefrine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Sufentanil.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Sufentanil is combined with Sertindole.]
[R06AX12, terfenadine, The metabolism of Sufentanil can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Sufentanil is combined with Bupropion.]
[N06AB08, fluvoxamine, The risk or severity of serotonin syndrome can be increased when Sufentanil is combined with Fluvoxamine.]
[C08CA02, felodipine, Sufentanil may decrease the antihypertensive activities of Felodipine.]
[C08EA01, fendiline, Sufentanil may increase the bradycardic activities of Fendiline.]
[N03AX26, fenfluramine, The risk or severity of serotonin syndrome can be increased when Sufentanil is combined with Fenfluramine.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Fenoprofen is combined with Sufentanil.]
[R03CC04, fenoterol, The risk or severity of adverse effects can be increased when Fenoterol is combined with Sufentanil.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Sufentanil is combined with Fentanyl.]
[R03CC02, albuterol, The risk or severity of hypertension can be increased when Sufentanil is combined with Salbutamol.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Sufentanil.]
[G04BD02, flavoxate, The risk or severity of adverse effects can be increased when Flavoxate is combined with Sufentanil.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Sufentanil is combined with Floctafenine.]
[J02AC01, fluconazole, The metabolism of Sufentanil can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Flunitrazepam.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Sufentanil is combined with Melitracen.]
[V03AZ01, ethanol, Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[N06AB03, fluoxetine, The risk or severity of serotonin syndrome can be increased when Sufentanil is combined with Fluoxetine.]
[N05AF01, flupenthixol, Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of hypotension and CNS depression can be increased when Fluphenazine is combined with Sufentanil.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Flurazepam.]
[S01BC04, flurbiprofen, The risk or severity of hypertension can be increased when Sufentanil is combined with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Sufentanil is combined with Fluspirilene.]
[N06BX17, adrafinil, The risk or severity of hypertension can be increased when Sufentanil is combined with Adrafinil.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Alcuronium is combined with Sufentanil.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Sufentanil is combined with Furazolidone.]
[J05AE10, darunavir, The metabolism of Sufentanil can be decreased when combined with Darunavir.]
[C03CA01, furosemide, The therapeutic efficacy of Furosemide can be decreased when used in combination with Sufentanil.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Sufentanil is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Sufentanil is combined with Amisulpride.]
[N06DA04, galantamine, Galantamine may increase the bradycardic activities of Sufentanil.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Gallamine is combined with Sufentanil.]
[C08DA02, gallopamil, Sufentanil may increase the bradycardic activities of Gallopamil.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Sufentanil.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Sufentanil is combined with Bifemelane.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be increased when Cabergoline is combined with Sufentanil.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Sufentanil is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Alfentanil.]
[A06AH02, alvimopan, The risk or severity of adverse effects can be increased when Sufentanil is combined with Alvimopan.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Sufentanil.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Sufentanil is combined with Glutethimide.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Sufentanil.]
[C05AE01, nitroglycerin, Sufentanil may decrease the antihypertensive activities of Nitroglycerin.]
[C02CA04, doxazosin, Sufentanil may decrease the antihypertensive activities of Doxazosin.]
[C07AB09, esmolol, Sufentanil may decrease the antihypertensive activities of Esmolol.]
[C09AA09, fosinopril, Sufentanil may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, Sufentanil may decrease the antihypertensive activities of Guanethidine.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Sufentanil.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Sufentanil is combined with Halothane.]
[N05AH04, quetiapine, The risk or severity of adverse effects can be increased when Quetiapine is combined with Sufentanil.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Sufentanil is combined with Iprazochrome.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Sufentanil is combined with Allobarbital.]
[C09CA01, losartan, Sufentanil may decrease the antihypertensive activities of Losartan.]
[B05CB03, magnesium citrate, The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Sufentanil.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Sufentanil.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Sufentanil.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Hexobarbital is combined with Sufentanil.]
[R03CC05, hexoprenaline, The risk or severity of hypertension can be increased when Sufentanil is combined with Hexoprenaline.]
[C08CA10, nilvadipine, The metabolism of Sufentanil can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypertension can be increased when Sufentanil is combined with Nimesulide.]
[C09AA04, perindopril, Sufentanil may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Sufentanil may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Sufentanil.]
[R05DA03, hydrocodone, Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Sufentanil.]
[A12BA02, potassium citrate, The therapeutic efficacy of Potassium citrate can be decreased when used in combination with Sufentanil.]
[G04BD06, propiverine, The risk or severity of adverse effects can be increased when Propiverine is combined with Sufentanil.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Sufentanil is combined with Prothipendyl.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.]
[C02AC06, rilmenidine, Sufentanil may decrease the antihypertensive activities of Rilmenidine.]
[R02AX02, ibuprofen, The risk or severity of hypertension can be increased when Sufentanil is combined with Ibuprofen.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Sufentanil.]
[N07XX04, sodium oxybate, Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[M01AG01, mefenamic acid, The risk or severity of hypertension can be increased when Sufentanil is combined with Mefenamic acid.]
[N06AA02, imipramine, The risk or severity of adverse effects can be increased when Imipramine is combined with Sufentanil.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Sufentanil is combined with Paclitaxel.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Sufentanil.]
[C03BA11, indapamide, The therapeutic efficacy of Indapamide can be decreased when used in combination with Sufentanil.]
[S01BC01, indomethacin, The risk or severity of hypertension can be increased when Indomethacin is combined with Sufentanil.]
[C02CA02, indoramin, Sufentanil may decrease the antihypertensive activities of Indoramin.]
[N06AX17, milnacipran, The risk or severity of serotonin syndrome can be increased when Sufentanil is combined with Milnacipran.]
[A03AA30, piperidolate, The risk or severity of adverse effects can be increased when Piperidolate is combined with Sufentanil.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Articaine.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Alprazolam.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Sufentanil is combined with Ramelteon.]
[R06AE01, buclizine, The risk or severity of adverse effects can be increased when Buclizine is combined with Sufentanil.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Sufentanil is combined with Alprenolol.]
[C03BA02, quinethazone, The therapeutic efficacy of Quinethazone can be decreased when used in combination with Sufentanil.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Sufentanil is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Sufentanil is combined with Iproniazid.]
[N05AA07, chlorproethazine, The risk or severity of hypotension and CNS depression can be increased when Chlorproethazine is combined with Sufentanil.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Sufentanil is combined with Isocarboxazid.]
[R03CC06, isoetharine, The risk or severity of hypertension can be increased when Isoetharine is combined with Sufentanil.]
[C09AA16, imidapril, Sufentanil may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Sufentanil.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Sufentanil.]
[J04AC01, isoniazid, The metabolism of Sufentanil can be decreased when combined with Isoniazid.]
[R03CB01, isoproterenol, The risk or severity of hypertension can be increased when Sufentanil is combined with Isoprenaline.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Sufentanil is combined with Isosorbide dinitrate.]
[C04AA01, isoxsuprine, The risk or severity of hypertension can be increased when Sufentanil is combined with Isoxsuprine.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Sufentanil.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Sufentanil is combined with Ketanserin.]
[J02AB02, ketoconazole, The metabolism of Sufentanil can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The risk or severity of adverse effects can be increased when Olanzapine is combined with Sufentanil.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Sufentanil is combined with Ketoprofen.]
[C01CA22, arbutamine, The risk or severity of hypertension can be increased when Sufentanil is combined with Arbutamine.]
[N04BC09, rotigotine, Sufentanil may increase the sedative activities of Rotigotine.]
[C07AG01, labetalol, Sufentanil may decrease the antihypertensive activities of Labetalol.]
[N04BB01, amantadine, The risk or severity of adverse effects can be increased when Amantadine is combined with Sufentanil.]
[C02AA05, deserpidine, Sufentanil may decrease the antihypertensive activities of Deserpidine.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Sufentanil.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Sufentanil.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Sufentanil is combined with Lacosamide.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Sufentanil is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Sufentanil.]
[C08EX01, lidoflazine, Sufentanil may increase the bradycardic activities of Lidoflazine.]
[C03DB01, amiloride, The therapeutic efficacy of Amiloride can be decreased when used in combination with Sufentanil.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Lisuride is combined with Sufentanil.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Lofepramine.]
[A07DA03, loperamide, Sufentanil may increase the bradycardic activities of Loperamide.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Lorazepam.]
[C10AA02, lovastatin, The metabolism of Sufentanil can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Sufentanil.]
[G04BX01, magnesium hydroxide, The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Sufentanil.]
[A12CC10, magnesium oxide, The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Sufentanil.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Sufentanil can be increased when used in combination with Magnesium sulfate.]
[L01EA03, nilotinib, The metabolism of Sufentanil can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The therapeutic efficacy of Mannitol can be decreased when used in combination with Sufentanil.]
[N06AA21, maprotiline, The risk or severity of adverse effects can be increased when Maprotiline is combined with Sufentanil.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Sufentanil.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Mecamylamine is combined with Sufentanil.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Sufentanil.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Sufentanil is combined with Meclofenamic acid.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Medazepam.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Sufentanil.]
[C03BA05, mefruside, The therapeutic efficacy of Mefruside can be decreased when used in combination with Sufentanil.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Sufentanil is combined with Melatonin.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Sufentanil.]
[C01CA11, mephentermine, Mephentermine may increase the analgesic activities of Sufentanil.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Sufentanil.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Sufentanil.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Sufentanil.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Sufentanil is combined with Meptazinol.]
[C03BC01, mersalyl, The therapeutic efficacy of Mersalyl can be decreased when used in combination with Sufentanil.]
[N05AC03, mesoridazine, The risk or severity of hypotension and CNS depression can be increased when Mesoridazine is combined with Sufentanil.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Sufentanil is combined with Paliperidone.]
[C01CA09, metaraminol, The risk or severity of hypertension can be increased when Metaraminol is combined with Sufentanil.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Sufentanil is combined with Dolasetron.]
[H01CB03, lanreotide, Sufentanil may increase the bradycardic activities of Lanreotide.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Sufentanil.]
[N06BA03, methamphetamine, Metamfetamine may increase the analgesic activities of Sufentanil.]
[A03AB07, methantheline, The risk or severity of adverse effects can be increased when Methantheline is combined with Sufentanil.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Sufentanil is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Sufentanil is combined with Methaqualone.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Sufentanil.]
[S01EC05, methazolamide, The therapeutic efficacy of Methazolamide can be decreased when used in combination with Sufentanil.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Sufentanil is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Sufentanil can be decreased when combined with Methimazole.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Sufentanil.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Sufentanil.]
[N02BG08, ziconotide, The risk or severity of adverse effects can be increased when Sufentanil is combined with Ziconotide.]
[N05AA02, methotrimeprazine, Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of hypertension can be increased when Sufentanil is combined with Methoxamine.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Sufentanil is combined with Methoxyflurane.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Sufentanil.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Sufentanil.]
[C02AB01, methyldopa, Sufentanil may decrease the antihypertensive activities of Methyldopa.]
[V04CG05, methylene blue, Sufentanil may increase the serotonergic activities of Methylene blue.]
[G02AB01, methylergonovine, The risk or severity of hypertension can be increased when Methylergometrine is combined with Sufentanil.]
[N06BA04, methylphenidate, The risk or severity of hypertension can be increased when Methylphenidate is combined with Sufentanil.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Sufentanil.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Sufentanil is combined with Methyprylon.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Sufentanil.]
[A03FA01, metoclopramide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Sufentanil.]
[C03BA08, metolazone, The therapeutic efficacy of Metolazone can be decreased when used in combination with Sufentanil.]
[C07AB02, metoprolol, Sufentanil may decrease the antihypertensive activities of Metoprolol.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Sufentanil is combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Sufentanil can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of hypertension can be increased when Sufentanil is combined with Aminophenazone.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Midazolam.]
[C01CA17, midodrine, The risk or severity of hypertension can be increased when Midodrine is combined with Sufentanil.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Sufentanil.]
[C09CA03, valsartan, Sufentanil may decrease the antihypertensive activities of Valsartan.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.]
[D11AX01, minoxidil, Sufentanil may decrease the antihypertensive activities of Minoxidil.]
[L01XX23, mitotane, The metabolism of Sufentanil can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, Lisdexamfetamine may increase the analgesic activities of Sufentanil.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Sufentanil is combined with Molindone.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Sufentanil.]
[C01BD01, amiodarone, The metabolism of Sufentanil can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of adverse effects can be increased when Amitriptyline is combined with Sufentanil.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Sufentanil.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Sufentanil.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Vecuronium is combined with Sufentanil.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Amobarbital is combined with Sufentanil.]
[N06AA17, amoxapine, The risk or severity of adverse effects can be increased when Amoxapine is combined with Sufentanil.]
[N03AB05, fosphenytoin, The metabolism of Sufentanil can be increased when combined with Fosphenytoin.]
[C07AA12, nadolol, Sufentanil may decrease the antihypertensive activities of Nadolol.]
[N04BC04, ropinirole, Sufentanil may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Sufentanil is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The therapeutic efficacy of Sufentanil can be decreased when used in combination with Nalbuphine.]
[V03AB15, naloxone, The metabolism of Sufentanil can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of adverse effects can be increased when Naltrexone is combined with Sufentanil.]
[S01GA01, naphazoline, Naphazoline may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.]
[N06BA01, amphetamine, Amphetamine may increase the analgesic activities of Sufentanil.]
[M02AA12, naproxen, The risk or severity of hypertension can be increased when Sufentanil is combined with Naproxen.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Sufentanil is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Sufentanil.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Remifentanil.]
[C01CX08, levosimendan, The risk or severity of adverse effects can be increased when Sufentanil is combined with Levosimendan.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Sufentanil is combined with Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Sufentanil.]
[N06AX23, desvenlafaxine, The risk or severity of serotonin syndrome can be increased when Sufentanil is combined with Desvenlafaxine.]
[C09CA07, telmisartan, Sufentanil may decrease the antihypertensive activities of Telmisartan.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Sufentanil is combined with Nialamide.]
[C08CA04, nicardipine, The risk or severity of adverse effects can be increased when Nicardipine is combined with Sufentanil.]
[C04AE02, nicergoline, The risk or severity of hypertension can be increased when Nicergoline is combined with Sufentanil.]
[C08CA05, nifedipine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Nifedipine.]
[M02AA17, niflumic acid, The risk or severity of hypertension can be increased when Sufentanil is combined with Niflumic acid.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Sufentanil is combined with Amyl Nitrite.]
[C08CA06, nimodipine, Sufentanil may decrease the antihypertensive activities of Nimodipine.]
[C08CA07, nisoldipine, Sufentanil may decrease the antihypertensive activities of Nisoldipine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Nitrazepam.]
[C08CA08, nitrendipine, Sufentanil may decrease the antihypertensive activities of Nitrendipine.]
[R07AX01, nitric oxide, The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Sufentanil.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Sufentanil is combined with Zaleplon.]
[N04BC05, pramipexole, Sufentanil may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, Sufentanil may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, Nitrous oxide may increase the cardiodepressant activities of Sufentanil.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Nomifensine.]
[C01CA03, norepinephrine, The risk or severity of hypertension can be increased when Norepinephrine is combined with Sufentanil.]
[C02KX01, bosentan, Sufentanil may decrease the antihypertensive activities of Bosentan.]
[N06AA10, nortriptyline, The risk or severity of adverse effects can be increased when Nortriptyline is combined with Sufentanil.]
[G02CA02, nylidrin, The risk or severity of hypertension can be increased when Sufentanil is combined with Nylidrin.]
[H01CB02, octreotide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Sufentanil.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Sufentanil is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Sufentanil is combined with Opium.]
[R03CB03, metaproterenol, The risk or severity of hypertension can be increased when Sufentanil is combined with Orciprenaline.]
[G04CA02, tamsulosin, The risk or severity of adverse effects can be increased when Tamsulosin is combined with Sufentanil.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Oxazepam.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Sufentanil is combined with Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Oxycodone is combined with Sufentanil.]
[C01DX03, oxyfedrine, The risk or severity of hypertension can be increased when Sufentanil is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of hypertension can be increased when Sufentanil is combined with Oxymetazoline.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Sufentanil is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Sufentanil is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Sufentanil.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.]
[M03AC01, pancuronium, The risk or severity of adverse effects can be increased when Pancuronium is combined with Sufentanil.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Papaverine.]
[N05CC05, paraldehyde, Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Sufentanil is combined with Pargyline.]
[G04BD11, fesoterodine, The risk or severity of adverse effects can be increased when Fesoterodine is combined with Sufentanil.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Sufentanil is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Sufentanil is combined with Penfluridol.]
[N02AD01, pentazocine, The therapeutic efficacy of Sufentanil can be decreased when used in combination with Pentazocine.]
[N05CA01, pentobarbital, The risk or severity of adverse effects can be increased when Pentobarbital is combined with Sufentanil.]
[N05AB10, perazine, The risk or severity of hypotension and CNS depression can be increased when Perazine is combined with Sufentanil.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Sufentanil is combined with Pergolide.]
[C08EX02, perhexiline, Sufentanil may increase the bradycardic activities of Perhexiline.]
[N05AB03, perphenazine, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Sufentanil.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Phenazocine.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Phenelzine.]
[N03AA02, phenobarbital, The risk or severity of adverse effects can be increased when Phenobarbital is combined with Sufentanil.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Sufentanil.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Phenoperidine.]
[C04AX02, phenoxybenzamine, Sufentanil may decrease the antihypertensive activities of Phenoxybenzamine.]
[A08AA01, phentermine, Phentermine may increase the analgesic activities of Sufentanil.]
[V03AB36, phentolamine, Sufentanil may decrease the antihypertensive activities of Phentolamine.]
[M02AA01, phenylbutazone, The risk or severity of hypertension can be increased when Sufentanil is combined with Phenylbutazone.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be increased when Phenylephrine is combined with Sufentanil.]
[R01BA01, phenylpropanolamine, The risk or severity of hypertension can be increased when Phenylpropanolamine is combined with Sufentanil.]
[N03AB02, phenytoin, The metabolism of Sufentanil can be increased when combined with Phenytoin.]
[C08CX01, mibefradil, Sufentanil may decrease the antihypertensive activities of Mibefradil.]
[N05AG02, pimozide, The risk or severity of adverse effects can be increased when Sufentanil is combined with Pimozide.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Sufentanil is combined with Pindolol.]
[J05AE01, saquinavir, The metabolism of Sufentanil can be decreased when combined with Saquinavir.]
[N05AC04, pipothiazine, The risk or severity of hypotension and CNS depression can be increased when Pipotiazine is combined with Sufentanil.]
[C09CA02, eprosartan, Sufentanil may decrease the antihypertensive activities of Eprosartan.]
[A02BX03, pirenzepine, The risk or severity of adverse effects can be increased when Pirenzepine is combined with Sufentanil.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Sufentanil is combined with Piritramide.]
[S01BC06, piroxicam, The risk or severity of hypertension can be increased when Piroxicam is combined with Sufentanil.]
[N02CX01, pizotyline, The risk or severity of adverse effects can be increased when Pizotifen is combined with Sufentanil.]
[J05AG02, delavirdine, The metabolism of Sufentanil can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, Sufentanil may decrease the antihypertensive activities of Irbesartan.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Sufentanil is combined with Proxibarbal.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Sufentanil.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Sufentanil is combined with Alosetron.]
[C03AA05, polythiazide, The therapeutic efficacy of Polythiazide can be decreased when used in combination with Sufentanil.]
[J05AE03, ritonavir, Ritonavir may decrease the excretion rate of Sufentanil which could result in a higher serum level.]
[C07AB01, practolol, Sufentanil may decrease the antihypertensive activities of Practolol.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Sufentanil is combined with Prazepam.]
[C02CA01, prazosin, Sufentanil may decrease the antihypertensive activities of Prazosin.]
[C01DX02, prenylamine, Sufentanil may increase the bradycardic activities of Prenylamine.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Sufentanil can be decreased when combined with Primaquine.]
[N03AA03, primidone, The risk or severity of adverse effects can be increased when Primidone is combined with Sufentanil.]
[S01HA05, procaine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Procarbazine.]
[N05AB04, prochlorperazine, The risk or severity of hypotension and CNS depression can be increased when Prochlorperazine is combined with Sufentanil.]
[N04AA04, procyclidine, The risk or severity of adverse effects can be increased when Procyclidine is combined with Sufentanil.]
[N05AA03, promazine, The risk or severity of adverse effects can be increased when Promazine is combined with Sufentanil.]
[R06AD02, promethazine, The risk or severity of adverse effects can be increased when Promethazine is combined with Sufentanil.]
[C01BC03, propafenone, The risk or severity of hypertension can be increased when Sufentanil is combined with Propafenone.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Sufentanil is combined with Propanidid.]
[A03AB05, propantheline, The risk or severity of adverse effects can be increased when Propantheline is combined with Sufentanil.]
[N05AC01, periciazine, The risk or severity of hypotension and CNS depression can be increased when Periciazine is combined with Sufentanil.]
[N05CM06, propiomazine, The risk or severity of adverse effects can be increased when Propiomazine is combined with Sufentanil.]
[N01AX10, propofol, Sufentanil may increase the sedative activities of Propofol.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Sufentanil.]
[C07AA05, propranolol, Sufentanil may decrease the antihypertensive activities of Propranolol.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Sufentanil is combined with Rizatriptan.]
[B01AC09, epoprostenol, Sufentanil may decrease the antihypertensive activities of Epoprostenol.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Sufentanil.]
[R01BA02, pseudoephedrine, Pseudoephedrine may increase the analgesic activities of Sufentanil.]
[N05AX12, aripiprazole, The risk or severity of adverse effects can be increased when Aripiprazole is combined with Sufentanil.]
[A03AB15, diphemanil, The risk or severity of adverse effects can be increased when Diphemanil is combined with Sufentanil.]
[A03AB09, isopropamide, The risk or severity of adverse effects can be increased when Isopropamide is combined with Sufentanil.]
[S01FA03, methscopolamine, The risk or severity of adverse effects can be increased when Methscopolamine is combined with Sufentanil.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Sufentanil.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Sufentanil is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Sufentanil is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Sufentanil is combined with Pyrantel.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Sufentanil is combined with Mepyramine.]
[C01BA01, quinidine, The risk or severity of adverse effects can be increased when Quinidine is combined with Sufentanil.]
[P01BC01, quinine, The risk or severity of adverse effects can be increased when Quinine is combined with Sufentanil.]
[C02AA01, rescinnamine, Sufentanil may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Sufentanil.]
[J04AB02, rifampin, The metabolism of Sufentanil can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, The risk or severity of hypertension can be increased when Sufentanil is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of hypertension can be increased when Sufentanil is combined with Ritodrine.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Sufentanil is combined with Oxitriptan.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Sufentanil is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Sufentanil is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of hypertension can be increased when Sufentanil is combined with Salicylic acid.]
[S01FA02, scopolamine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Sufentanil.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Sufentanil.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Sufentanil is combined with Selegiline.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Sufentanil is combined with Obinutuzumab.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Sufentanil.]
[C07AA07, sotalol, The risk or severity of adverse effects can be increased when Sotalol is combined with Sufentanil.]
[C03DA01, spironolactone, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Sufentanil.]
[C01DA14, isosorbide mononitrate, The risk or severity of adverse effects can be increased when Sufentanil is combined with Isosorbide mononitrate.]
[H02CA04, levoketoconazole, The metabolism of Sufentanil can be decreased when combined with Levoketoconazole.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Sufentanil is combined with Tiaprofenic acid.]
[C03CC01, ethacrynic acid, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Sufentanil.]
[R03BB01, ipratropium bromide, The risk or severity of adverse effects can be increased when Ipratropium is combined with Sufentanil.]
